Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.
Pediatrics. 1999 Aug; 104(2):e20.Ped

Abstract

OBJECTIVE

To assess the risk for substance use disorders (SUD) associated with previous exposure to psychotropic medication in a longitudinal study of boys with attention-deficit/hyperactivity disorder (ADHD).

METHODS

The cumulative incidence of SUD throughout adolescence was compared in 56 medicated subjects with ADHD, 19 nonmedicated subjects with ADHD, and 137 non-ADHD control subjects.

RESULTS

Unmedicated subjects with ADHD were at a significantly increased risk for any SUD at follow-up compared with non-ADHD control subjects (adjusted OR: 6.3 [1.8-21.6]). Subjects with ADHD medicated at baseline were at a significantly reduced risk for a SUD at follow-up relative to untreated subjects with ADHD (adjusted OR: 0.15 [0.04-0.6]). For each SUD subtype studied, the direction of the effect of exposure to pharmacotherapy was similar to that seen for the any SUD category.

CONCLUSIONS

Consistent with findings in untreated ADHD in adults, untreated ADHD was a significant risk factor for SUD in adolescence. In contrast, pharmacotherapy was associated with an 85% reduction in risk for SUD in ADHD youth.

Authors+Show Affiliations

Biederman J
Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA. biederman@helix.mgh.harvard.edu
Wilens T
No affiliation info available
Mick E
No affiliation info available
Spencer T
No affiliation info available
Faraone SV
No affiliation info available

MeSH

AdolescentAttention Deficit Disorder with HyperactivityCase-Control StudiesCentral Nervous System StimulantsChildHumansIncidenceLongitudinal StudiesMaleRegression AnalysisRisk FactorsSubstance-Related Disorders

Pub Type(s)

Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10429138

Citation

Biederman, J, et al. "Pharmacotherapy of Attention-deficit/hyperactivity Disorder Reduces Risk for Substance Use Disorder." Pediatrics, vol. 104, no. 2, 1999, pp. e20.
Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):e20.
Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S. V. (1999). Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics, 104(2), e20.
Biederman J, et al. Pharmacotherapy of Attention-deficit/hyperactivity Disorder Reduces Risk for Substance Use Disorder. Pediatrics. 1999;104(2):e20. PubMed PMID: 10429138.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. AU - Biederman,J, AU - Wilens,T, AU - Mick,E, AU - Spencer,T, AU - Faraone,S V, PY - 1999/8/3/pubmed PY - 1999/8/3/medline PY - 1999/8/3/entrez SP - e20 EP - e20 JF - Pediatrics JO - Pediatrics VL - 104 IS - 2 N2 - OBJECTIVE: To assess the risk for substance use disorders (SUD) associated with previous exposure to psychotropic medication in a longitudinal study of boys with attention-deficit/hyperactivity disorder (ADHD). METHODS: The cumulative incidence of SUD throughout adolescence was compared in 56 medicated subjects with ADHD, 19 nonmedicated subjects with ADHD, and 137 non-ADHD control subjects. RESULTS: Unmedicated subjects with ADHD were at a significantly increased risk for any SUD at follow-up compared with non-ADHD control subjects (adjusted OR: 6.3 [1.8-21.6]). Subjects with ADHD medicated at baseline were at a significantly reduced risk for a SUD at follow-up relative to untreated subjects with ADHD (adjusted OR: 0.15 [0.04-0.6]). For each SUD subtype studied, the direction of the effect of exposure to pharmacotherapy was similar to that seen for the any SUD category. CONCLUSIONS: Consistent with findings in untreated ADHD in adults, untreated ADHD was a significant risk factor for SUD in adolescence. In contrast, pharmacotherapy was associated with an 85% reduction in risk for SUD in ADHD youth. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/10429138/full_citation DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓104]

Related Citations

    More

    Others Viewed